Critical Analysis: DaVita (NYSE:DVA) & Daxor (NASDAQ:DXR)

DaVita (NYSE:DVA) and Daxor (NASDAQ:DXR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk and analyst recommendations.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for DaVita and Daxor, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DaVita	0	3	0	0	2.00
Daxor	0	0	1	0	3.00

DaVita currently has a consensus target price of $164.00, indicating a potential upside of 21.17%. Daxor has a consensus target price of $25.00, indicating a potential upside of 135.85%. Given Daxor’s stronger consensus rating and higher probable upside, analysts plainly believe Daxor is more favorable than DaVita.

Earnings & Valuation

This table compares DaVita and Daxor”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DaVita	$13.16 billion	0.74	$936.34 million	$10.17	13.31
Daxor	$2.13 million	24.06	N/A	N/A	N/A

DaVita has higher revenue and earnings than Daxor.

Institutional & Insider Ownership

90.1% of DaVita shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 1.5% of DaVita shares are owned by company insiders. Comparatively, 59.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

DaVita has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.13, suggesting that its stock price is 113% less volatile than the S&P 500.

Profitability

This table compares DaVita and Daxor’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DaVita	6.35%	369.39%	4.62%
Daxor	N/A	N/A	N/A

Summary

DaVita beats Daxor on 6 of the 11 factors compared between the two stocks.

About DaVita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the provision of acute inpatient dialysis services and related laboratory services; and transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.